Introducing Two New Highly Effective ADC Payloads For Cancer Therapeutics

Antibody-drug conjugates (ADCs) are revolutionizing cancer therapy, offering powerful solutions with targeted action against cancer cells while minimizing adverse effects. Despite the growing interest in ADC development, access to safe and effective payloads and linkers remains a challenge.

Samsung Biologics is committed to empowering the ADC community by providing two novel payloads—derivatives of camptothecin and duocarmycin. These payloads boast best-in-class efficacy and safety, validated through extensive in vitro and in vivo studies. By offering these agents, we enable ADC developers to advance their research without financial burdens or the need for specialized medicinal chemistry expertise.

In this webinar, we will introduce these innovative payloads and showcase how to integrate them into your ADC development through our "Easy to Access Technology" program. Gain valuable insights and explore real-world applications to elevate your projects.

Key Learning Objectives:

• The importance of selecting high-quality payloads in ADC development
• Physicochemical and biological profiles of our novel payloads
• How to easily test our payloads for your ADC antibodies under a straightforward arrangement.